How to access Joenja from Saudi Arabia — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A Saudi patient diagnosed with activated phosphoinositide 3-kinase delta syndrome (APDS) — a rare inherited primary immunodeficiency characterised by recurrent infections, lymphoproliferation, and increased malignancy risk — may receive a prescription for Joenja (leniolisib) from their treating clinical immunologist. Joenja is FDA-approved as the first therapy specifically indicated for APDS, developed by Pharming Group. APDS is often underdiagnosed; in Saudi Arabia and the broader Gulf region, genetic confirmation is increasingly available through academic medical centres. In the Kingdom, Joenja is not locally registered, which is why your immunologist will navigate the named-patient import pathway on your behalf.

This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Joenja is a small-molecule selective PI3Kδ inhibitor, taken as an oral tablet twice daily. Eligibility is based on genetic confirmation of a pathogenic variant in PIK3CD or PIK3R1, clinical features consistent with APDS, and ongoing management by a clinical immunologist or immunology-haematology team familiar with primary immunodeficiencies. Your physician will confirm diagnosis, document baseline immune status and lymphoproliferative burden, and set up on-treatment monitoring of immune-cell counts, infection profile, and liver function per FDA labeling. Because Joenja is an oral therapy, in-country infrastructure requirements are modest once the prescribing team has the monitoring plan in place.

Is Joenja legally importable into Saudi Arabia?

Yes — through the Saudi Food and Drug Authority (SFDA) named-patient import framework. The SFDA route allows a Saudi-licensed physician to request import of a medicine not locally registered when: (a) the medicine has been approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent locally registered alternative is suitable, (c) the treating physician takes clinical responsibility, and (d) the importing party documents chain of custody. Applications are reviewed by the SFDA Drug Sector.

For APDS — a rare inherited immune disease with no other FDA-approved disease-specific therapy — the named-patient rationale is straightforward to articulate. Saudi tertiary centres with primary-immunodeficiency expertise (notably in Riyadh and Jeddah) have experience with rare-disease named-patient imports.

How the pathway works, step by step

1. Consultation with your treating clinical immunologist. Genetic confirmation of APDS (PIK3CD or PIK3R1 variant) and a written clinical rationale documenting disease burden and the absence of a locally registered alternative.
2. Baseline assessment. Immune-cell counts, immunoglobulin levels, lymphoproliferation assessment, liver enzymes, and infection history are compiled.
3. SFDA named-patient application. Your physician or the hospital's importing pharmacy files the application, including clinical rationale, genetic report, patient reference, and chain-of-custody plan.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Joenja from authorised distribution.
5. Ambient shipment. Joenja tablets ship at ambient controlled conditions with chain-of-custody documentation.
6. Arrival and dispensing. The hospital pharmacy releases the bottle to the patient with physician instructions for twice-daily dosing and monitoring schedule.

What documentation your physician needs

Your physician will typically need to provide:

• A clinical rationale letter confirming APDS diagnosis, genetic report, disease burden, and Joenja as the indicated treatment
• Verification of their Saudi medical licence (SCFHS / MOH)
• A copy of the PIK3CD or PIK3R1 genetic diagnostic report
• Patient identifier (anonymised reference preferred)
• Planned dosing schedule and safety monitoring plan (immune cells, LFTs, infection surveillance)

Reserve Meds provides a physician documentation kit that bundles the templates SFDA reviewers expect to see for rare primary-immunodeficiency named-patient imports.

Costs and timing

Joenja's US cash-pay reference price sits in an indicative 2026 range of roughly USD 45,000–50,000 for a 30-day supply, with total course cost driven by duration on therapy. APDS is a lifelong condition, so annual cost implications are substantial. International logistics, SFDA documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.

Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 14–28 days from the moment a complete SFDA application is submitted. Refills ship on a rolling basis against your monthly dispensing schedule.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

A culturally-aware note: APDS is inherited, and Saudi families with high rates of consanguinity may have multiple members affected or at risk. Our concierge coordination can include parents, siblings, and extended-family members in education and evaluation pathways at the patient's direction.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Joenja specifically, we provide:

• Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and for SFDA review.
• Logistics. Chain-of-custody shipment coordination to your prescribing hospital pharmacy.
• Concierge case lead. A named point of contact for your family and your physician through intake, first dispense, and long-term refills.

What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating clinical immunologist. We operate on a waitlist basis during our pre-launch phase.

Frequently asked

Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient framework with appropriate documentation. Cross-border named-patient import for rare-disease therapies is a recognised and routine mechanism. See our trust and compliance page.

Is Joenja a cure for APDS? Joenja is a disease-modifying therapy that targets the underlying molecular driver of APDS. Pivotal studies have shown improvements in lymphoproliferation and immune parameters. Your immunologist will discuss realistic outcome expectations.

Do my other affected family members need separate applications? Yes. Each patient requires their own named-patient application, clinical dossier, and genetic confirmation. Our concierge team coordinates family applications together where multiple members are affected.

How is it monitored? Monitoring includes immune-cell subsets, immunoglobulin levels, infection surveillance, and liver function. Your immunologist schedules these.

Will insurance cover this? Cash-pay is the default. Some Saudi private insurers consider rare-disease imports case by case; we supply documentation for your submission but do not process insurance claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Joenja coordination in Saudi Arabia.

Add me to the Joenja waitlist

---

Composite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.